Innate Pharma (IPHA) Capital Expenditures (2019 - 2025)

Innate Pharma has reported Capital Expenditures for 7 years, with the latest figure at -$162966.1 in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures rose 61.0% year-over-year to -$162966.1; the trailing twelve-month figure through Dec 2025 stood at -$958441.8 (up 15.33% YoY), and the FY2024 full-year result was $417820.8, up 10.64% from the prior year.
• Capital Expenditures for Q4 2025 stood at -$162966.1, up from -$417820.8 in the prior quarter.
• The five-year high for Capital Expenditures was -$162966.1 in Q4 2025, with the low at -$1.1 million in Q4 2021.
• Historically, Capital Expenditures has averaged -$455086.2 across 5 years, with a median of -$397737.9 in 2023.
• Annual changes were most pronounced in 2022 — Capital Expenditures sank 55.06% — and 2025, when it jumped 61.0%.
• Innate Pharma's Capital Expenditures stood at -$1.1 million in 2021, then jumped by 48.64% to -$545832.3 in 2022, then jumped by 30.81% to -$377654.9 in 2023, then dropped by 10.64% to -$417820.8 in 2024, then jumped by 61.0% to -$162966.1 in 2025.
• The last three Capital Expenditures figures came in at -$162966.1 (Q4 2025), -$417820.8 (Q4 2024), and -$377654.9 (Q4 2023), per Business Quant data.